{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:08:27Z","timestamp":1776182907800,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jpet.2026.103816","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:10:05Z","timestamp":1769040605000},"page":"103816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical characterization of pharmacokinetics, enzyme occupancy, and pharmacodynamics of soticlestat (TAK-935), a novel cholesterol 24-hydroxylase inhibitor"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9609","authenticated-orcid":false,"given":"Maki","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Toshiya Nishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3264-1406","authenticated-orcid":false,"given":"Tatsuki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Sunahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayuri","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syunsuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Igari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyasu","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsutoshi","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruaki","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2026.103816_bib1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1146\/annurev.biochem.78.072407.103859","article-title":"Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain","volume":"78","author":"Russell","year":"2009","journal-title":"Annu Rev Biochem"},{"issue":"12 Pt A","key":"10.1016\/j.jpet.2026.103816_bib2","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.bbalip.2016.09.011","article-title":"Cholesterol 24-hydroxylase: brain cholesterol metabolism and beyond","volume":"1861","author":"Moutinho","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"25","key":"10.1016\/j.jpet.2026.103816_bib3","doi-asserted-by":"crossref","first-page":"22980","DOI":"10.1074\/jbc.M303415200","article-title":"Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover","volume":"278","author":"Lund","year":"2003","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.jpet.2026.103816_bib4","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1194\/jlr.M300164-JLR200","article-title":"Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration","volume":"44","author":"Xie","year":"2003","journal-title":"J Lipid Res"},{"issue":"16","key":"10.1016\/j.jpet.2026.103816_bib5","doi-asserted-by":"crossref","first-page":"12228","DOI":"10.1021\/acs.jmedchem.1c00864","article-title":"Discovery of soticlestat, a potent and selective inhibitor for cholesterol 24-hydroxylase (CH24H)","volume":"64","author":"Koike","year":"2021","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.jpet.2026.103816_bib6","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00259-021-05565-z","article-title":"Preclinical characterization of [18F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase","volume":"49","author":"Koike","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.jpet.2026.103816_bib7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/cpdd.1526","article-title":"Physiologically based pharmacokinetic modeling to predict drug-drug interactions of soticlestat as a victim of CYP induction and inhibition, and as a perpetrator of CYP and P-glycoprotein inhibition","volume":"14","author":"Jia","year":"2025","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"10.1016\/j.jpet.2026.103816_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1213","article-title":"Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function","volume":"12","author":"Yin","year":"2024","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.jpet.2026.103816_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74036-6","article-title":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice","volume":"10","author":"Nishi","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jpet.2026.103816_bib11","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/epi.17232","article-title":"Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor","volume":"63","author":"Nishi","year":"2022","journal-title":"Epilepsia"},{"issue":"44","key":"10.1016\/j.jpet.2026.103816_bib12","doi-asserted-by":"crossref","first-page":"17290","DOI":"10.1523\/JNEUROSCI.2619-13.2013","article-title":"The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors","volume":"33","author":"Paul","year":"2013","journal-title":"J Neurosci"},{"issue":"9","key":"10.1016\/j.jpet.2026.103816_bib13","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/00001756-200506210-00007","article-title":"24S-hydroxycholesterol induces inflammatory gene expression in primary human neural cells","volume":"16","author":"Alexandrov","year":"2005","journal-title":"Neuroreport"},{"issue":"2\u20133","key":"10.1016\/j.jpet.2026.103816_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neulet.2008.08.037","article-title":"Necroptosis contributes to the NMDA-induced excitotoxicity in rat\u2019s cultured cortical neurons","volume":"447","author":"Li","year":"2008","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.1016\/j.jpet.2026.103816_bib15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.bbrc.2014.02.010","article-title":"Diverse functions of 24(S)-hydroxycholesterol in the brain","volume":"446","author":"Noguchi","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"Pt B","key":"10.1016\/j.jpet.2026.103816_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.steroids.2015.02.003","article-title":"Induction of oxiapoptophagy on 158N murine oligodendrocytes treated by 7-ketocholesterol-, 7\u03b2-hydroxycholesterol-, or 24(S)-hydroxycholesterol: protective effects of \u03b1-tocopherol and docosahexaenoic acid (DHA; C22:6 n-3)","volume":"99","author":"Nury","year":"2015","journal-title":"Steroids"},{"issue":"10","key":"10.1016\/j.jpet.2026.103816_bib17","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/epi.17367","article-title":"A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA)","volume":"63","author":"Hahn","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpet.2026.103816_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106646","article-title":"A phase 1b\/2a study of soticlestat as adjunctive therapy in participants with developmental and\/or epileptic encephalopathies","volume":"174","author":"Halford","year":"2021","journal-title":"Epilepsy Res"},{"issue":"11","key":"10.1016\/j.jpet.2026.103816_bib21","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1111\/bcp.14854","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects","volume":"87","author":"Wang","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jpet.2026.103816_bib22","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1111\/bcp.15225","article-title":"Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers","volume":"88","author":"Wang","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpet.2026.103816_bib24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fphar.2014.00174","article-title":"Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research","volume":"5","author":"Tuntland","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpet.2026.103816_bib25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3389\/fphar.2020.00997","article-title":"Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges","volume":"11","author":"Zou","year":"2020","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.jpet.2026.103816_bib26","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/cts.13517","article-title":"Population pharmacokinetics, enzyme occupancy, and 24S-hydroxycholesterol modeling of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in healthy adults","volume":"16","author":"Yin","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jpet.2026.103816_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114612","article-title":"Design and synthesis of aryl-piperidine derivatives as potent and selective PET tracers for cholesterol 24-hydroxylase (CH24H)","volume":"240","author":"Ikeda","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"12","key":"10.1016\/j.jpet.2026.103816_bib28","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.2967\/jnumed.123.265912","article-title":"Clinical characterization of [18F]T-008, a cholesterol 24-hydroxylase PET ligand: dosimetry, kinetic modeling, variability, and soticlestat occupancy","volume":"64","author":"Constantinescu","year":"2023","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.jpet.2026.103816_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.575","article-title":"Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: a microdialysis study in rats","volume":"8","author":"Chen","year":"2020","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.jpet.2026.103816_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/138920006774832578","article-title":"Tissue distribution and pharmacodynamics: a complicated relationship","volume":"7","author":"Lin","year":"2006","journal-title":"Curr Drug Metab"},{"issue":"12","key":"10.1016\/j.jpet.2026.103816_bib31","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jpet.2026.103816_bib32","series-title":"Assay Guidance Manual","article-title":"In vivo receptor occupancy in rodents by LC-MS\/MS","author":"Jesudason","year":"2004"},{"issue":"5","key":"10.1016\/j.jpet.2026.103816_bib33","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/jphp.12030","article-title":"In-vivo rat striatal 5-HT4 receptor occupancy using non-radiolabelled SB207145","volume":"65","author":"Nirogi","year":"2013","journal-title":"J Pharm Pharmacol"},{"issue":"12","key":"10.1016\/j.jpet.2026.103816_bib34","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1021\/cn500072r","article-title":"Identifying novel radiotracers for PET imaging of the brain: application of LC-MS\/MS to tracer identification","volume":"5","author":"Barth","year":"2014","journal-title":"ACS Chem Neurosci"},{"issue":"9","key":"10.1016\/j.jpet.2026.103816_bib35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrd2082","article-title":"Drug-target residence time and its implications for lead optimization","volume":"5","author":"Copeland","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"15\u201316","key":"10.1016\/j.jpet.2026.103816_bib36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2013.02.010","article-title":"Pharmacokinetics and the drug-target residence time concept","volume":"18","author":"Dahl","year":"2013","journal-title":"Drug Discov Today"},{"issue":"48","key":"10.1016\/j.jpet.2026.103816_bib37","doi-asserted-by":"crossref","first-page":"30178","DOI":"10.1074\/jbc.272.48.30178","article-title":"Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro","volume":"272","author":"Bj\u00f6rkhem","year":"1997","journal-title":"J Biol Chem"},{"issue":"20","key":"10.1016\/j.jpet.2026.103816_bib38","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1002\/jssc.201500719","article-title":"Method development for the determination of 24S-hydroxycholesterol in human plasma without derivatization by high-performance liquid chromatography with tandem mass spectrometry in atmospheric pressure chemical ionization mode","volume":"38","author":"Sugimoto","year":"2015","journal-title":"J Sep Sci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526000145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526000145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:13:36Z","timestamp":1776179616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526000145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0022356526000145"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.103816","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical characterization of pharmacokinetics, enzyme occupancy, and pharmacodynamics of soticlestat (TAK-935), a novel cholesterol 24-hydroxylase inhibitor","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.103816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Takeda Pharmaceutical Company Limited. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"103816"}}